BOULDER, Colo.--(BUSINESS WIRE)--Dec. 20, 2004--Glucon, developer of a continuous, noninvasive, glucose monitoring technology for home and clinical use, today named Suzuken Co., Ltd (TSE:9987), Japan’s largest pharmaceuticals distributor, as one of the company’s strategic investors. Suzuken Co.'s equity investment in Glucon is part of the $14.8 million financing round made public in September 2004. Triangle Technologies was instrumental in helping to form the current strategic relationship between Glucon and Suzuken.
